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OBJECTIVE — The purpose of this study was to estimate the risks of nontraumatic lower-
extremity amputations (LEAs) in patients with type 1 diabetes.
RESEARCH DESIGN AND METHODS — We identiﬁed 31,354 patients with type 1
diabetes (15,001 women and 16,353 men) in the Swedish Inpatient Register between 1975 and
2004. The incidence of nontraumatic LEAs was followed up until 31 December 2004 by cross-
linkage in the Inpatient Register and linkage to the Death and Migration registers. Poisson
regression modeling was used to compare the risks of nontraumatic LEAs during different
calendar periods of follow-up, with adjustment for both sex and attained age at follow-up.
Standardized incidence ratios (SIRs) were used to estimate the relative risks (RRs) with the age-,
sex-, and calendar period–matched general Swedish population as reference. The cumulative
probability of nontraumatic LEAs was calculated by the Kaplan-Meier method.
RESULTS — In total, 465 patients with type 1 diabetes underwent nontraumatic LEAs. The
risk was lower during the most recent calendar period (2000–2004) than during the period
before 2000 (RR 0.6 [95% CI 0.5–0.8]). However, even in this most recent period, the risk for
nontraumatic LEAs among these relatively young patients was 86-fold higher than that in the
matched general population (SIR 85.8 [72.9–100.3]). By age 65 years, the cumulative proba-
bility of having a nontraumatic LEA was 11.0% for women with type 1 diabetes and 20.7% for
men with type 1 diabetes.
CONCLUSIONS — Although the risks appeared to have declined in recent years, patients
with type 1 diabetes still have a very high risk for nontraumatic LEAs.
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U
lceration of the foot is the most
common ﬁrst indicator of impend-
ing nontraumatic lower-extremity
amputations (LEAs) related to diabetes,
and it has been estimated worldwide that
one lower limb is amputated every 30 s as
a consequence of this condition. Of all
nontraumatic LEAs, 50–70% are associ-
atedwithdiabetes(1).Diabeticfootulcer-
ation involves a complex underlying
pathophysiology and a multifactorial ap-
proach to care, including preventive foot
care,aggressivemanagementofacutefoot
ulceration,controlofinfections,andearly
recognition of vascular disease, which are
all of major importance in this context
(2,3). In addition to reducing quality of
life and enhancing morbidity, disability,
and premature mortality (4,5), diabetic
foot complications are a considerable ﬁ-
nancial burden on society and individual
patients (6), accounting for 20% of the
total expenditure on health care for pa-
tients with diabetes (1).
The incidence of nontraumatic LEAs
asaconsequenceofdiabetesisconsidered
to be a key indicator of the quality of foot
care for such patients (7). In 1989, the
World Health Organization and Interna-
tional Diabetes Federation initiated a
joint program called the Saint Vincent
Declaration for improving the care of
patients with diabetes (8). The goals set
forth included a 50% reduction in
major nontraumatic LEAs caused by di-
abetes. It is unclear whether this goal has
been attained in the case of type 1 diabe-
tes, as most relevant epidemiological
studies reported have been concerned
with patients with type 2 diabetes or a
mixture of type 1 and type 2 diabetic pa-
tients (9–11). Therefore, the aim of this
register-based study involving a large co-
hort was to obtain an estimate of the risk
of nontraumatic LEAs in patients with type
1 diabetes.
RESEARCH DESIGN AND
METHODS— This study was ap-
proved by the Regional Ethics Committee
at the Karolinska Institutet.
In 1964/1965, the National Board of
HealthandWelfareestablishedtheSwed-
ish Inpatient Register and different coun-
ties joined on different occasions
thereafter until nationwide coverage was
attained in 1987. By 1977, 73% of all
Swedish counties were included (12).
Each record in this register corresponds
toonehospitaladmissionandcontains,in
addition to the patient’s national registra-
tion number (a unique identiﬁer assigned
to all residents of Sweden), the dates of
admission and discharge, codes indicat-
ingallsurgicalproceduresperformedand
thediagnosisatthetimeofdischarge.Co-
hort enrollment started on different dates
in the different counties, but in all cases it
was at least 2 years after uninterrupted
full-coverage registration was achieved in
the county. The ICD coding used before
the 10th revision in 1997 does not allow
us to distinguish between patients with
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had type 2 diabetes that had advanced
into a state of insulin dependence. For
these reasons, an age of 31 years at the
time of index hospitalization for diabetes
(even if this date preceded the start of our
cohort recruitment) was considered here
to be an obligatory criterion for entry into
our cohort of patients with type 1 diabe-
tes. Further details concerning how we
identiﬁed type 1 diabetic patients from
the Swedish Inpatient Register have been
reported elsewhere (13).
We ﬁrst identiﬁed 31,950 records of
patientswithadischargediagnosisoftype
1 diabetes. Their records were linked to
the Register of Total Population, the Em-
igration Register, and the Causes of Death
Register. These linkages resulted in the
exclusionof42recordsforwhichnational
registration numbers could not be found
in any of the registers, i.e., records with-
out a link to any currently or previously
existing individual. Also excluded were
58 patients with amputation before the
index hospitalization and 496 patients
with other inconsistencies found in the
record linkages. Thus, our ﬁnal cohort
consisted of 31,354 patients with type 1
diabetes.
Follow-up
The cohort members were followed from
immediately after the index hospitaliza-
tion for type 1 diabetes until a ﬁrst hospi-
talization with a recorded nontraumatic
LEA, emigration from Sweden, migration
to a county with no or incomplete Inpa-
tient Register coverage, death, or the end
offollow-up(31December2004),which-
ever occurred ﬁrst. Occurrences of non-
traumatic LEAs were identiﬁed through
cross-linkages in the Inpatient Register.
Amputationsabovethekneeweredeﬁned
by operation codes 8780 or 8781 before
1998 and NGQ09, NFQ19, or NFQ99
thereafter. Amputations below the knee
were deﬁned by operation codes 8770 or
8771 before 1998 and NGQ19, NHQ09,
NHQ11, or NGQ99 thereafter. Amputa-
tionsbelowtheankleweredeﬁnedbyop-
eration codes 8750 or 8760 before 1998
and NHQ16, NHQ17, NHQ12, NHQ13,
Table 1—Characteristics of the patients hospitalized at least once for type 1 diabetes, 1975–
2004, Sweden
Women Men Total
n 15,001 16,353 31,354
Age at enrollment (years) 19.9  11.3 19.6  11.1 19.7  11.1
Mean calendar year at entry 1990 1991 1991
Follow-up duration (years) 13.1  7.6 12.0  7.4 12.5  7.5
Person-years accumulated 196,928 196,206 393,134
Patients with (%)
Ophthalmic complications* 20.6 16.4 18.4
Diabetic nephropathy† 9.2 8.5 8.8
Neurological complications‡ 7.1 7.1 7.1
No. of nontraumatic LEAs§ 201 264 465
Amputation above knee 18 11 29
Amputation below knee 82 111 193
Amputation below ankle 101 142 243
Age at diagnosis (years) 45.1  7.6 45.6  8.1 45.4  7.8
Data are means  SD unless indicated otherwise. *Ophthalmic complications deﬁned by ICD-7 codes
260.20,260.21,and260.29,ICD-8codes250.01,250.02,and250.03,ICD-9code250E,andICD-10codes
E10.3, E11.3, E12.3, E13.3, and E14.3. †Diabetic nephropathy deﬁned by ICD-7 code 260.30, ICD-8 code
250.40, ICD-9 code 250D, and ICD-10 codes E10.2, E11.2, E12.2, E13.2, and E14.2. ‡Neurological
complications deﬁned by ICD-7 codes 260.40 and 260.49, ICD-8 code 250.05, ICD-9 code 250F, and
ICD-10 codes E10.4, E11.4, E12.4, E13.4, and E14.4. §LEA deﬁned by the operation code: amputation
below the ankle was deﬁned by operation codes 8750 or 8760 before 1998 and NHQ16, NHQ17, NHQ12,
NHQ13, NHQ14, or NHQ99 afterwards; amputation above the ankle but below the knee was deﬁned by
operation codes 8770 or 8771 before 1998 and NGQ19, NHQ09, NHQ11, or NGQ99 afterwards; and
amputationabovethekneewasdeﬁnedbyoperationcodes8780or8781before1998andNGQ09,NFQ19,
or NFQ99 afterwards. Traumatic amputations of the lower-extremity were excluded.
Table 2—RRs (95% CIs) for nontraumatic LEAs, according to calendar period at follow-up, sex, and attained age, among patients hospitalized
at least once for type 1 diabetes, 1975–2004, Sweden
All nontraumatic LEAs Amputation above knee
Amputation
below knee but
above ankle Amputation below ankle
Obs* RR (95% CI) Obs RR (95% CI) Obs RR (95% CI) Obs RR (95% CI)
Calendar period at
follow-up
1975–1999 307 Reference 21 Reference 132 Reference 154 Reference
2000–2004 158 0.6 (0.5–0.8) 8 0.5 (0.2–1.3) 61 0.5 (0.4–0.7) 89 0.7 (0.5–0.9)
Sex
Male 264 Reference 11 Reference 111 Reference 142 Reference
Female 201 0.7 (0.5–0.8) 18 1.5 (0.7–3.1) 82 0.6 (0.5–0.8) 101 0.6 (0.5–0.8)
Attained age (years)
40 126 Reference 12 Reference 37 Reference 77 Reference
40–49 204 9.7 (7.7–12.1) 12 5.8 (2.6–12.9) 94 15.4 (10.5–22.6) 98 7.5 (5.6–10.1)
50–59 121 21.3 (16.5–27.5) 4 7.4 (2.3–23.4) 59 37.1 (24.4–56.5) 58 16.1 (11.3–22.8)
60 14 42.9 (24.3–75.6) 1 33.7 (4.0–280.8) 3 34.7 (10.5–114.7) 10 45.9 (23.2–90.9)
Ptrend 0.0001 0.0001 0.0001 0.0001
Variables listed in the table were mutually adjusted. *Obs, number of observed nontraumatic LEAs in each category.
Jonasson and Associates
DIABETES CARE, VOLUME 31, NUMBER 8, AUGUST 2008 1537NHQ14,orNHQ99thereafter.Traumatic
LEAs were excluded from our analysis.
Statistical analyses
To compare the risk for nontraumatic
LEAs during different calendar periods of
follow-up with adjustment for sex and at-
tained age at follow-up, multivariable
Poisson regression models were ﬁtted
with the logarithm of the number of per-
son-yearsobservedastheoffset,assuming
multiplicative relationships between the
outcome and the explanatory variables.
Pearson’s 
2 statistic was used to estimate
the goodness of ﬁt for the multivariable
Poisson regression models. To test the
trend of the relative risks (RRs) associated
with attained age at follow-up, the cate-
gorical variable of attained age-groups at
follow-up was treated as a semicontinu-
ous variable in the regression model.
Standardized incidence ratios (SIRs),
the ratios of the observed to the expected
numbers of ﬁrst hospitalization for non-
traumaticLEAs,wereusedasameasureof
the RRs. The corresponding 95% CIs
were calculated by assuming that the
number of observed events followed a
Poissondistribution(14).Tocalculatethe
expected rates, we ﬁrst counted the num-
bers of ﬁrst occurrence of nontraumatic
LEAamongthegeneralpopulationbyage
(in 5-year groups), sex, and 5-year calen-
dar period in every county in Sweden.
Because a large proportion of all nontrau-
matic LEAs among young patients are at-
tributable to type 1 diabetes, we then
subtracted the stratum-speciﬁc outcome
number of observed events in our cohort
fromthenumberofnontraumaticLEAsin
the respective stratum in the general pop-
ulation. Stratum-speciﬁc incidence rates
werecalculatedbydividingthenumberof
nontraumaticLEAsineachstratumbythe
corresponding general population count.
The expected number of nontraumatic
LEAs in our cohort was derived by multi-
plying the observed number of person-
years in the cohort by the age-, sex-, and
calendarperiod–matchedincidencerates.
The cumulative probability of devel-
opment of a nontraumatic LEA by age
65 years was calculated separately for
women and men using the Kaplan-Meier
method.Inaddition,thelog-ranktestwas
applied to test the statistical signiﬁcance
of any differences observed between
groups. All statistical analyses were per-
formed with SAS software (version 9.1;
SAS Institute, Cary, NC).
RESULTS— The 15,001 women and
16,353 men in our cohort, with a mean
age of 19.7 years at entry, exhibited no
obvious differences with respect to base-
line characteristics (Table 1). Of our co-
hort members, 18% exhibited diabetic
retinopathy, 9% nephropathy, and 7%
neuropathy recorded at any given point.
On average, our cohort members were
followed for 12.5 years, yielding a total of
393,134 person-years at risk. A total of
465cohortmembersunderwentnontrau-
matic LEAs: 29 above the knee, 193 be-
lowthekneebutabovetheankle,and243
below the ankle. The mean age at non-
Figure 1—The cumulative probability of nontraumatic LEA among type 1 diabetic patients, estimated by the Kaplan-Meier method.
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25.2–69.7 years).
The risk of nontraumatic LEAs for
type 1 diabetic patients was 40% lower
(95%CI20–50%)duringthemostrecent
calendar period of follow-up (2000–
2004) than that during the previous cal-
endar period. Women demonstrated a
lowerriskthanmen(RR0.7[95%CI0.5–
0.8]), and the RR clearly increased with
increasing attained age at follow-up (Ta-
ble 2). Analyses based on the site of am-
putations revealed similar patterns,
except that women appeared to have a
higher risk for amputation above the
knee,althoughthisdifferencewasnotsta-
tistically signiﬁcant.
In comparison with the age-, sex-,
and calendar period–matched general
population, patients with type 1 diabetes
demonstrated notably elevated risks for
nontraumatic LEAs. For example, during
themostrecentcalendarperiodoffollow-
up (2000–2004), the SIR was as high as
85.8 (95% CI 72.9–100.3) for all non-
traumatic LEAs: 19.6 (8.5–38.6) for am-
putation above the knee, 86.8 (66.4–
111.5) for amputation below the knee
but above the ankle, and 121.8 (97.9–
149.9) for amputation below the ankle.
Figure 1 illustrates the cumulative
probability of development of nontrau-
matic LEAs among patients with type 1
diabetes, as estimated by the Kaplan-
Meier method. As we can see, this proba-
bility was almost negligible for both men
andwomenbeforeage30years,increased
in a similar manner for both sexes during
thenextdecadeoflife,butincreasedmore
rapidlyinmenafterage40years.Thus,by
age 65 years, the cumulative probability
of nontraumatic LEA was 11.0% for
women and 20.7% for men (Plog-rank 
0.01).
CONCLUSIONS — This investiga-
tion revealed that patients with type 1 di-
abetes have substantial absolute and
relative risks for nontraumatic LEAs. As
many as 1 of 10 women and 1 of 5 men
with this disease may have undergone a
nontraumatic LEA by age 65 years. The
clear reduction in the risk of nontrau-
matic LEAs among patients with type 1
diabetes in the most recent calendar pe-
riod of follow-up might be due to the in-
troduction of a national program for the
prevention and treatment of foot ulcer-
ation in patients with diabetes (15), al-
though a longer period of follow-up is
required to conﬁrm this trend.
Our ﬁnding that men with type 1 di-
abetes have higher risks for nontraumatic
LEAs than women with type 1 diabetes
is consistent with previous reports (9,
11,16). This more pronounced cumula-
tive risk in men may reﬂect several
factors, including the fact that smoking is
more common among men (17) and that
woundshealmoreefﬁcientlyinwomenas
a consequence of their expression of the
estrogen receptor- (18,19).
The strengths of the present study in-
cludeitscohortdesign,theuseofmedical
information recorded by doctors rather
than self-reports by patients, and the vir-
tually complete follow-up due to the
requirement for hospital care for amputa-
tions and high coverage of the present co-
hort by the Swedish Inpatient Register.
Nonetheless, this investigation also has
certain limitations. First, we did not have
access to information concerning treat-
ment and the state of metabolic control of
our patients. Second, patients with type 1
diabeteswhohadneverbeenhospitalized
were not identiﬁed, and failure to include
these patients would lead to an overesti-
mation of the risk for nontraumatic LEAs
inourpatientswithtype1diabetes.How-
ever, because most of such patients in
Sweden are highly likely to be hospital-
izedatthetimeofdiagnosisinSweden,in
accordancewiththeNationalProgramfor
Diabetes Care (20,21), the proportion
missed is considered to be very small in-
deed.Third,althoughwehavesubtracted
type 1 diabetes–related cases of nontrau-
maticLEAsinourcalculationoftheback-
ground rates, some of these cases might
have been missed, especially during the
earliercalendarperiodsoffollow-up.This
false inﬂation of background rates in the
generalpopulationmighthavecausedthe
underestimation of the actual RRs for
nontraumatic LEAs among our patients.
Insummary,eventhoughourdatado
suggest that the risk of nontraumatic LEA
among patients with type 1 diabetes has
attenuated in recent years, patients diag-
nosed with this disease before age 31
yearsnonethelesshavestrikinglyhighab-
solute and relative risks of nontraumatic
LEAs. The apparent decline in the risks
indicates that recent preventive efforts
have been effective, but the ﬁndings doc-
umented here emphasize the need for the
unrelenting application of measures de-
signed to prevent nontraumatic LEAs
early in the course of type 1 diabetes.
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